KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) FCF Margin (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of FCF Margin data on record, last reported at 414.55% in Q3 2025.

  • For Q3 2025, FCF Margin fell 22968.0% year-over-year to 414.55%; the TTM value through Sep 2025 reached 304.08%, down 11316.0%, while the annual FY2024 figure was 180.01%, 3467.0% up from the prior year.
  • FCF Margin reached 414.55% in Q3 2025 per NKTR's latest filing, down from 409.62% in the prior quarter.
  • Across five years, FCF Margin topped out at 159.88% in Q4 2024 and bottomed at 629.51% in Q4 2021.
  • Average FCF Margin over 5 years is 311.47%, with a median of 304.21% recorded in 2021.
  • Peak YoY movement for FCF Margin: skyrocketed 36517bps in 2022, then plummeted -24832bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 629.51% in 2021, then surged by 58bps to 264.34% in 2022, then rose by 25bps to 197.97% in 2023, then increased by 19bps to 159.88% in 2024, then crashed by -159bps to 414.55% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 414.55% in Q3 2025, 409.62% in Q2 2025, and 468.98% in Q1 2025.